![](https://endpts.com/wp-content/uploads/2023/03/Renee-Aguiar-Lucander-Calliditas-tile.jpg)
Renee Aguiar-Lucander, Calliditas CEO
Calliditas claims mid-stage win for rare liver disease drug
Calliditas Therapeutics’ NOX enzyme inhibitor succeeded in a Phase 2b trial in people with a rare liver disease that features inflammation and injury in the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.